Integra LifeSciences Posts Q3 Profit; Reaffirms FY26 Outlook

Integra LifeSciences (IART) reported Q3 2026 revenue of $411.2M, up 2.3% YoY, and returned to profitability with GAAP net income of $14.9M. Adjusted EPS rose to $0.59. The company reaffirmed its FY26 outlook, expecting revenue of $1.634B-$1.654B and adjusted EPS of $2.30-$2.40.

Original reporting
Published Oct 21, 2026, 11:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

Earnings and guidance provide fresh data for valuation models; pre‑market price decline suggests immediate market reaction.

02

Market read

The earnings release is the primary catalyst for short‑term price movement in IART.

03

What to watch

Potential upside from flood‑damage insurance recovery and upcoming product launches not reflected in guidance.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences reported Q3 results, returning to profitability and completed a $2.1 bn debt refinancing.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Q3 2026 earnings released with profit and reaffirmed FY26 outlook; premarket price down 4.35% on the news.

Expected impact

likely downward pressure as market prices in modest guidance and higher debt load

Evidence & confidence

Profit after loss and reaffirmed outlook were expected; guidance range is flat, prompting sell pressure.

Market effects

Medical device sector may see slight pullback as peers watch Integra's debt refinancing and modest growth.

U.S. biotech/medical stocks could face short‑term pressure.

Limited to investors focused on U.S. healthcare equities.

Counterpoint

If the market overreacts to modest guidance, a bounce could occur on the debt refinancing flexibility.

Key entities

  • Integra LifeSciences Holdings Corp.

    Medical device manufacturer (ticker IART).

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.